Cargando…
Proportion of Ugandans with pre-pandemic SARS-CoV-2 cross-reactive CD4+ and CD8+ T-cell responses: A pilot study
The estimated mortality rate of the SARS-CoV-2 pandemic varied greatly around the world. In particular, multiple countries in East, Central, and West Africa had significantly lower rates of COVID-19 related fatalities than many resource-rich nations with significantly earlier wide-spread access to l...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431628/ https://www.ncbi.nlm.nih.gov/pubmed/37585383 http://dx.doi.org/10.1371/journal.pgph.0001566 |
_version_ | 1785091247025684480 |
---|---|
author | Namuniina, Annemarie Muyanja, Enoch S. Biribawa, Victoria M. Okech, Brenda A. Ssemaganda, Aloysious Price, Matt A. Hills, Nancy Nanteza, Ann Bagaya, Bernard Ssentalo Weiskopf, Daniela Riou, Catherine Reynolds, Steven J. Galiwango, Ronald M. Redd, Andrew D. |
author_facet | Namuniina, Annemarie Muyanja, Enoch S. Biribawa, Victoria M. Okech, Brenda A. Ssemaganda, Aloysious Price, Matt A. Hills, Nancy Nanteza, Ann Bagaya, Bernard Ssentalo Weiskopf, Daniela Riou, Catherine Reynolds, Steven J. Galiwango, Ronald M. Redd, Andrew D. |
author_sort | Namuniina, Annemarie |
collection | PubMed |
description | The estimated mortality rate of the SARS-CoV-2 pandemic varied greatly around the world. In particular, multiple countries in East, Central, and West Africa had significantly lower rates of COVID-19 related fatalities than many resource-rich nations with significantly earlier wide-spread access to life-saving vaccines. One possible reason for this lower mortality could be the presence of pre-existing cross-reactive immunological responses in these areas of the world. To explore this hypothesis, an exploratory study of stored peripheral blood mononuclear cells (PBMC) from Ugandans collected from 2015–2017 prior to the COVID-19 pandemic (n = 29) and from hospitalized Ugandan COVID-19 patients (n = 3) were examined using flow-cytometry for the presence of pre-existing SARS-CoV-2 cross-reactive CD4+ and CD8+ T-cell populations using four T-cell epitope mega pools. Of pre-pandemic participants, 89.7% (26/29) had either CD4+ or CD8+, or both, SARS-CoV-2 specific T-cell responses. Specifically, CD4+ T-cell reactivity (72.4%) and CD8+ T-cell reactivity (65.5%) were relatively similar, and 13 participants (44.8%) had both types of cross-reactive types of T-cells present. There were no significant differences in response by sex in the population, however this may be in part due to the limited sample size examined. The rates of cross-reactive T-cell populations in this exploratory Ugandan population appears higher than previous estimates from resource-rich countries like the United States (20–50% reactivity). It is unclear what role, if any, this cross-reactivity played in decreasing COVID-19 related mortality in Uganda and other African countries, but does suggest that a better understanding of global pre-existing immunological cross-reactivity could be an informative data of epidemiological intelligence moving forward. |
format | Online Article Text |
id | pubmed-10431628 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-104316282023-08-17 Proportion of Ugandans with pre-pandemic SARS-CoV-2 cross-reactive CD4+ and CD8+ T-cell responses: A pilot study Namuniina, Annemarie Muyanja, Enoch S. Biribawa, Victoria M. Okech, Brenda A. Ssemaganda, Aloysious Price, Matt A. Hills, Nancy Nanteza, Ann Bagaya, Bernard Ssentalo Weiskopf, Daniela Riou, Catherine Reynolds, Steven J. Galiwango, Ronald M. Redd, Andrew D. PLOS Glob Public Health Research Article The estimated mortality rate of the SARS-CoV-2 pandemic varied greatly around the world. In particular, multiple countries in East, Central, and West Africa had significantly lower rates of COVID-19 related fatalities than many resource-rich nations with significantly earlier wide-spread access to life-saving vaccines. One possible reason for this lower mortality could be the presence of pre-existing cross-reactive immunological responses in these areas of the world. To explore this hypothesis, an exploratory study of stored peripheral blood mononuclear cells (PBMC) from Ugandans collected from 2015–2017 prior to the COVID-19 pandemic (n = 29) and from hospitalized Ugandan COVID-19 patients (n = 3) were examined using flow-cytometry for the presence of pre-existing SARS-CoV-2 cross-reactive CD4+ and CD8+ T-cell populations using four T-cell epitope mega pools. Of pre-pandemic participants, 89.7% (26/29) had either CD4+ or CD8+, or both, SARS-CoV-2 specific T-cell responses. Specifically, CD4+ T-cell reactivity (72.4%) and CD8+ T-cell reactivity (65.5%) were relatively similar, and 13 participants (44.8%) had both types of cross-reactive types of T-cells present. There were no significant differences in response by sex in the population, however this may be in part due to the limited sample size examined. The rates of cross-reactive T-cell populations in this exploratory Ugandan population appears higher than previous estimates from resource-rich countries like the United States (20–50% reactivity). It is unclear what role, if any, this cross-reactivity played in decreasing COVID-19 related mortality in Uganda and other African countries, but does suggest that a better understanding of global pre-existing immunological cross-reactivity could be an informative data of epidemiological intelligence moving forward. Public Library of Science 2023-08-16 /pmc/articles/PMC10431628/ /pubmed/37585383 http://dx.doi.org/10.1371/journal.pgph.0001566 Text en https://creativecommons.org/publicdomain/zero/1.0/This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication. |
spellingShingle | Research Article Namuniina, Annemarie Muyanja, Enoch S. Biribawa, Victoria M. Okech, Brenda A. Ssemaganda, Aloysious Price, Matt A. Hills, Nancy Nanteza, Ann Bagaya, Bernard Ssentalo Weiskopf, Daniela Riou, Catherine Reynolds, Steven J. Galiwango, Ronald M. Redd, Andrew D. Proportion of Ugandans with pre-pandemic SARS-CoV-2 cross-reactive CD4+ and CD8+ T-cell responses: A pilot study |
title | Proportion of Ugandans with pre-pandemic SARS-CoV-2 cross-reactive CD4+ and CD8+ T-cell responses: A pilot study |
title_full | Proportion of Ugandans with pre-pandemic SARS-CoV-2 cross-reactive CD4+ and CD8+ T-cell responses: A pilot study |
title_fullStr | Proportion of Ugandans with pre-pandemic SARS-CoV-2 cross-reactive CD4+ and CD8+ T-cell responses: A pilot study |
title_full_unstemmed | Proportion of Ugandans with pre-pandemic SARS-CoV-2 cross-reactive CD4+ and CD8+ T-cell responses: A pilot study |
title_short | Proportion of Ugandans with pre-pandemic SARS-CoV-2 cross-reactive CD4+ and CD8+ T-cell responses: A pilot study |
title_sort | proportion of ugandans with pre-pandemic sars-cov-2 cross-reactive cd4+ and cd8+ t-cell responses: a pilot study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431628/ https://www.ncbi.nlm.nih.gov/pubmed/37585383 http://dx.doi.org/10.1371/journal.pgph.0001566 |
work_keys_str_mv | AT namuniinaannemarie proportionofugandanswithprepandemicsarscov2crossreactivecd4andcd8tcellresponsesapilotstudy AT muyanjaenochs proportionofugandanswithprepandemicsarscov2crossreactivecd4andcd8tcellresponsesapilotstudy AT biribawavictoriam proportionofugandanswithprepandemicsarscov2crossreactivecd4andcd8tcellresponsesapilotstudy AT okechbrendaa proportionofugandanswithprepandemicsarscov2crossreactivecd4andcd8tcellresponsesapilotstudy AT ssemagandaaloysious proportionofugandanswithprepandemicsarscov2crossreactivecd4andcd8tcellresponsesapilotstudy AT pricematta proportionofugandanswithprepandemicsarscov2crossreactivecd4andcd8tcellresponsesapilotstudy AT hillsnancy proportionofugandanswithprepandemicsarscov2crossreactivecd4andcd8tcellresponsesapilotstudy AT nantezaann proportionofugandanswithprepandemicsarscov2crossreactivecd4andcd8tcellresponsesapilotstudy AT bagayabernardssentalo proportionofugandanswithprepandemicsarscov2crossreactivecd4andcd8tcellresponsesapilotstudy AT weiskopfdaniela proportionofugandanswithprepandemicsarscov2crossreactivecd4andcd8tcellresponsesapilotstudy AT rioucatherine proportionofugandanswithprepandemicsarscov2crossreactivecd4andcd8tcellresponsesapilotstudy AT reynoldsstevenj proportionofugandanswithprepandemicsarscov2crossreactivecd4andcd8tcellresponsesapilotstudy AT galiwangoronaldm proportionofugandanswithprepandemicsarscov2crossreactivecd4andcd8tcellresponsesapilotstudy AT reddandrewd proportionofugandanswithprepandemicsarscov2crossreactivecd4andcd8tcellresponsesapilotstudy |